BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 29, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

HOB-294: Phase III data

Hisamitsu said data from a Japanese Phase III trial in patients with OAB showed that once-daily HOB-294 for 12 weeks met undisclosed primary endpoints for efficacy compared to placebo. Additionally, HOB-294 was...

Read the full 137 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >